GlaxoSmithKline PLC's $5.1bn acquisition of Tesaro Inc. sped up the company's revamp of its cancer R&D engine, but deals of that size will be outliers for now, CEO Emma Walmsley indicated on 25 September.
Speaking at the opening of a $120m biologics manufacturing and R&D facility outside Philadelphia, the exec said GSK needs to...








